5th Dec 2019 12:20
(Alliance News) - GlaxoSmithKline PLC on Thursday said ViiV Healthcare has completed submission of a new drug application to the US Food & Drug Administration, seeking approval of fostemsavir.
ViiV Healthcare is majority owned by Glaxo, with fellow pharmaceutical firms Pfizer Inc and Shionogi Ltd as a minority shareholders.
Fostemsavir is an investigational attachment inhibitor for the treatment of HIV-1 infection, which is being developed for use in combination with other antiretroviral agents in heavily treatment-experienced adults.
"Fostemsavir may provide an important treatment option for the group of people living with HIV who, for a variety of reasons, are not able to suppress their virus with other medicines and could be left with few or no treatments available to them," said ViiV Healthcare Chief Executive Deborah Waterhouse.
She added: "In keeping with our mission of leaving no person with HIV behind, we have overcome many barriers to bring this important new medicine to people living with HIV, including investing in what is a very complex manufacturing process."
Glaxo shares were trading 0.4% higher in London on Thursday afternoon at 1,715.40 pence each.
By Evelina Grecenko; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline